Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

NCT02924376 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Cholangiocarcinoma

Interventions

DRUG: Pemigatinib

Sponsor

Incyte Corporation